Is ALNY a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

878 people get ALNY articles and Market Currents by email alert.

Get email alerts on ALNY »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Biotech Bubble: Alnylam Triples Despite Setbacks And Insider Selling
Richard Pearson • Mon, Feb 25 • 4 Comments
Medicines Company Braces For 2015 With Alnylam PCSK9 Deal
EP Vantage • Mon, Feb 4
Alnylam: Rally On No News Leaves Room For Downside
Apsara Biotechnology Research • Thu, Jan 24 • 3 Comments
When Compared To Isis, Alnylam's Valuation Does Not Make Sense
Apsara Biotechnology Research • Wed, Dec 19, 2012 • 9 Comments
Alnylam Falls Behind The Competition
Chimera Research Group • Tue, Dec 18, 2012 • 1 Comment
Alnylam: Further Evidence That The Stock Is Overvalued
Apsara Biotechnology Research • Mon, Nov 19, 2012 • 6 Comments
Alnylam: No Approved Drugs, No Promising Candidates, No Justification For $1 Billion Valuation
Apsara Biotechnology Research • Thu, Nov 15, 2012 • 15 Comments
Alnylam Pushes Forward In Amyloidosis After Pfizer Setback
EP Vantage • Tue, Jul 17, 2012 • 1 Comment
Will Alnylam Raise Money Soon?
Stephen Simpson • Mon, Jul 16, 2012 • 13 Comments
Alnylam Far From Primetime, But Still An Intriguing Prospect
Stephen Simpson • Mon, Jul 9, 2012 • 5 Comments
Future Trends In RNAi Drug Delivery
Dan Lukehart • Wed, Mar 28, 2012 • 8 Comments
What Alnylam Doesn't Want You To Know
Dan Lukehart • Fri, Mar 16, 2012 • 8 Comments
Good News For Alnylam: PBL Making Baulcombe Patent Widely Available
Dan Lukehart • Sun, Mar 11, 2012 • 2 Comments
Alnylam Looks Nearly Left For Dead
Stephen Simpson • Thu, Dec 29, 2011 • 5 Comments
Alnylam's Drug Technologies Could Be Revolutionary
David White • Tue, Dec 6, 2011 • 7 Comments
Alnylam Wins Another China Patent for siRNA
ChinaBio Today • Thu, Apr 30, 2009 • 1 Comment
Alnylam and RNAi: The Truth Hurts
Derek Lowe • Thu, Aug 21, 2008 • 6 Comments
Alnylam Pharmaceuticals: A Falling Star
Mike Huckman • Thu, Aug 21, 2008 • 2 Comments
Alnylam and Takeda Form Alliance In RNAi
Eben Tessari • Tue, May 27, 2008
Alnylam Signs First Transaction with China Biotech on RNAi Research Products
ChinaBio Today • Mon, Mar 24, 2008

To learn more about Seeking Alpha Pro, click here.

2 Biotechs With Recent Intensive Insider Selling
Markus Aarnio • Sun, Jun 16 • 8 Comments
Tekmira Pharmaceuticals: An Interesting Long-Term Investment
Alexander Maxwell • Thu, Jun 13 • 3 Comments
Cramer's Lightning Round - The All-Clear For Allstate (6/6/13)
SA Editor Miriam Metzinger • Fri, Jun 7
3 Pharmaceuticals With Strong Potential
FAF Research • Wed, Jun 5
The Beginning Of A Shift At Tekmira: From Focus On Delivery, To Therapy
PropThink • Tue, Apr 23 • 1 Comment
Biotechs With Staggering Potential: Grant Zeng
Life Sciences Report • Fri, Apr 5 • 5 Comments
Cramer's Mad Money - Which Company Should Buy Netflix? (4/3/13)
SA Editor Miriam Metzinger • Thu, Apr 4 • 4 Comments
Investors Seeing Huge Potential In RNA Drug Developers
Brian L. Wilson • Fri, Mar 8 • 2 Comments
Isis: FDA Approval Of Kynamro Promises A Bright Future For Company
Prohost Biotech • Fri, Feb 1 • 24 Comments
With The RNAi Sector Heating Up Again This Is Now The Undervalued Biotech Stock To Watch
M. E. Garza • Fri, Feb 1 • 1 Comment
2 Biotech Stocks To Consider This Week In The Wake Of Trial Data
Matt Schilling • Thu, Dec 13, 2012 • 3 Comments
Applying The Venture Capital Model To Public Companies: Hugh Cleland
Life Sciences Report • Wed, Nov 21, 2012 • 2 Comments
Tekmira Could Offer Stockholders Huge Rewards
C.R. Jackson • Thu, Nov 15, 2012 • 1 Comment
7 Biotech Stocks Trading At Steep Discount To Target Price
Kapitall • Thu, Nov 15, 2012
Casey Analyst Forecasts Explosive Biotech Growth
Life Sciences Report • Thu, Oct 11, 2012
Don't Judge Monsanto By A Slow Quarter
Stephen Simpson • Wed, Oct 3, 2012 • 6 Comments
Biotech: On The Way To Meeting Highly Ambitious Expectations
Prohost Biotech • Mon, Sep 10, 2012 • 1 Comment
Monsanto, Alnylam To Apply Genomics To Agricultural Pests
Alan Kotok • Sun, Sep 2, 2012 • 6 Comments
8 Intriguing Small Cap Biotechnology Companies For Your Consideration
Joe Springer • Mon, Aug 20, 2012 • 2 Comments
China Biotech In Review: Deals, Trials And Regulations
ChinaBio Today • Sun, Jul 15, 2012

Lightning Round: Visa, Micron & More

at CNBC.com (Jun 6, 2013)
Alnylam to Webcast Presentation at Goldman Sachs 34th Annual Global Healthcare Conference

Business Wire (Jun 6, 2013)
Alnylam to Webcast Presentation at Deutsche Bank 38th Annual dbAccess Health Care Conference

Business Wire (May 21, 2013)
Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinate Synthase-1 (ALAS-1) for the Treatment of Porphyria

Business Wire (May 17, 2013)
Alnylam to Webcast Presentation at 2013 UBS Global Healthcare Conference

Business Wire (May 15, 2013)
Alnylam to Webcast Presentation at 2013 Bank of America Merrill Lynch Health Care Conference

Business Wire (May 8, 2013)
Alnylam Pharmaceuticals Reports First Quarter 2013 Financial Results

Business Wire (May 6, 2013)
Alnylam to Webcast Conference Call Discussing First Quarter 2013 Financial Results

Business Wire (Apr 29, 2013)
Alnylam to Webcast Presentation at 12th Annual Needham Healthcare Conference

Business Wire (Apr 23, 2013)
Cramer Highlights Biotech 'Game Changers'

at CNBC.com (Apr 3, 2013)
Alnylam Initiates Phase I Clinical Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)

Business Wire (Mar 18, 2013)
Alnylam to Webcast Presentation at Barclays Global Healthcare Conference

Business Wire (Mar 5, 2013)
Alnylam to Webcast Presentation at Cowen and Company 33rd Annual Health Care Conference

Business Wire (Feb 26, 2013)
Lightning Round: Vonage, Bank of America, Molycorp and More

at CNBC.com (Feb 22, 2013)
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results

Business Wire (Feb 7, 2013)
Alnylam to Webcast Presentation at Upcoming Investor Conferences

Business Wire (Feb 5, 2013)
The Medicines Company and Alnylam Form Strategic Alliance to Develop and Commercialize RNAi Therapeutics Targeting PCSK9 for the Treatment of Hypercholesterolemia

Business Wire (Feb 4, 2013)
Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2012 Financial Results

Business Wire (Jan 31, 2013)
Alnylam and Collaborators Publish Results from Phase I Clinical Trial and Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer

Business Wire (Jan 30, 2013)
Alnylam Pharmaceuticals Announces Exercise of Over-Allotment Option in Public Offering of Common Stock

Business Wire (Jan 16, 2013)

ALNY vs. ETF Alternatives

Company Description

Currently, there's no company description for ALNY.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, June 11, 9:47 AM Morgan Stanley initiates Alnylam Pharmaceuticals (ALNY +1.6%) at Overweight with a $35 price target, saying the company may be poised "to move from a science based company to a commercial one." The comments are reminiscent of the rationale behind Deutsche Bank's recent note on the stock. Comment! [Healthcare]
Friday, May 24, 9:28 AM Deutsche Bank starts Alnylam Pharmaceuticals (ALNY) at Buy with a $40 price target representing a 42.5% premium to Thursday's close. Analyst Alethia Young says the company "has the chance to unlock significant long-term value as they commercialize their assets in the clinic during 2017 and beyond, leading to $4B+ in unadjusted sales." Comment! [Healthcare]
Friday, May 17, 9:46 AM Alnylam Pharmaceuticals (ALNY -0.2%) pares the early gains it racked up after saying preclinical data demonstrate RNAi therapeutics targeting ALAS-1 can suppress the "toxic heme biosynthesis intermediaries that cause the symptoms and disease pathology of acute intermittent porphyria." The company says the findings support its ALN-AS1 program. (PR) Comment! [Healthcare]
Monday, May 6, 4:09 PM Alnylam Pharmaceuticals (ALNY): Q1 EPS of -$0.15. Revenue of $18.6M beats by $3.04M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, May 6, 12:10 AM Notable earnings after Monday’s close: ALNY, AMTG, APC, ARRY, BSFT, CECO, CHUY, DPM, ENOC, EOG, FSLR, FST, FTR, GDP, GSM, GWAY, HIMX, HOLX, LGCY, MELI, MKTG, MMLP, MR, NOG, NRP, OTTR, PAA, PEGA, PNG, RKUS, SGY, SMG, SNTS, STAG, VNO, WMS Comment! [Earnings]
Sunday, May 5, 5:35 PM Notable earnings after Monday’s close: ALNY, AMTG, APC, ARRY, BSFT, CECO, CHUY, DPM, ENOC, EOG, FSLR, FST, FTR, GDP, GSM, GWAY, HIMX, HOLX, LGCY, MELI, MKTG, MMLP, MR, NOG, NRP, OTTR, PAA, PEGA, PNG, RKUS, SGY, SMG, SNTS, STAG, VNO, WMS Comment! [Earnings]
Monday, February 11, 11:00 AM Alnylam Pharmaceuticals (ALNY -3.4%) dips after MLV cut the shares to Hold from Buy. The firm says it prefers to take a cautious stance ahead of pending details of disease-modifying data from its lead partnered programs. One such program is its strategic alliance with The Medicines Co. (MDCO -3%) to develop ALN-PCS, an RNAi therapeutic program for the treatment of hypercholesterolemia. Comment! [Healthcare, On the Move]
Thursday, February 7, 4:08 PM Alnylam Pharma (ALNY): Q4 Gaap-EPS of -$1.20 beats by $0.25. Revenue of $8.5M misses by $7.32M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, February 7, 12:10 AM Notable earnings after Thursday’s close: AGNC, ALNY, ASYS, ATHN, ATVI, AVNR, CSTR, DCT, FLT, G, HAS, LNKD, MCHP, NCR, NFG, NUAN, OPEN, PRI, RGC, RSG, RVBD, SNCR, SPWR, TSRA, UBNT, WWWW, XL Comment! [Earnings]
Wednesday, February 6, 5:35 PM Notable earnings after Thursday’s close: AGNC, ALNY, ASYS, ATHN, ATVI, AVNR, CSTR, DCT, FLT, G, HAS, LNKD, MCHP, NCR, NFG, NUAN, OPEN, PRI,RGC, RSG, RVBD, SNCR, SPWR, TSRA, UBNT, WWWW, XL Comment! [Earnings]
Monday, February 4, 12:49 PM The Medicines Company (MDCO -1.5%) says it's formed an exclusive global alliance with Alnylam Pharmaceuticals (ALNY -2.6%) for the development and commercialization of ALNY's ALN-PCS RNAi therapeutic program for the treatment of hypercholesterolemia. The deal could net ALNY $205M plus double-digit royalties if the collaboration is successful, and an early-stage trial has already showed success. Comment! [Healthcare]
Monday, February 4, 8:22 AM The Medicines Company (MDCO) is licensing the rights to cholesterol-lowering drug ALN-PCS from Alnylam Pharmaceuticals (ALNY), with Medicines paying $25M up front, as much as $180M in milestones, and then royalties. The treatment inhibits a protein called PCSK9 and is seen as an alternative to statins such as Lipitor. However, ALN-PCS is only in Phase I trials. Comment! [Healthcare]
Thursday, January 17, 1:05 PM Alnyam Pharmaceuticals (ALNY -1.3%) slips on further dilution as the underwriters of its recent secondary offering exercise options to purchase an additional 1.2M shares at $20.13. The purchase increases the size of the offering from 8M to 9.2M and boosts the net proceeds to ALNY to $173.8M. Comment! [Healthcare, On the Move]
Monday, January 14, 4:10 PM Alnylam Pharmaceuticals (ALNY) announces a secondary offering of approximately $125M. All of the shares in the offering are to be sold by Alnylam. JPMorgan (JPM) and Morgan Stanley (MS) are acting as joint book-runners. 1 Comment [Healthcare]
Wednesday, December 12, 2012, 2:45 PM Alnylam Pharmaceuticals (ALNY +4%) trades up after Piper Jaffray raised its rating to Neutral and increased its price target from $19 to $25. Piper notes that with the Tekmira litigation behind them, ALNY can now focus more on clinical progress. Specifically, the firm expects the drug developer to have Phase II data on its ALN-TTR02 this summer to prepare for pivotal studies by year-end, adding that ALNY also plans to file applications with the FDA on sub-cutaneous hemophilia therapy formulations of ALN-TTR02 and ALN-AT3. Comment! [Healthcare, On the Move]
Monday, December 10, 2012, 2:08 PM Alnylam Pharmaceuticals (ALNY +5.2%) trades up after reporting encouraging pre-clinical data for its RNAi therapeutic program to treat of hemophilia and other bleeding disorders. The drug candidate produced up to a four-fold increase in thrombin - a protein that plays a role in blood coagulation - in testing with non-human primates. The company says it eventually plans to have five different medications in clinical development by the end of 2015. Comment! [Healthcare, On the Move]

ltfinger
Returning Upgrades (3/28/13): $AIZ, $ALGT, $ALNY, $ALV, $ANSS, $APH, $ARII, $BDC, $BMRN, $BOFI, $BRK-B, $CAVM, $CBD, $CBS, $CELG, $CGNX
Apr 1, 9:09 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Returning Upgrades (3/5/13): $ALNY, $CBS, $HME, $NTES, $PRLB
Mar 5, 11:49 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
Morning Coffee, Day Trading Watchlist: $AAPL $CRUS $ALNY | SharePlanner http://bit.ly/U0LMwD
Jan 16, 9:19 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Tony Kau
Just closed out $GNTX $FCFS longs, $KMB $ALNY shorts for 5-day mkt neutral return of 3%! http://bit.ly/IjKuDO
5/1/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
SRPT has superior RNA technology. ALNY has superior RNA delivery tech (via MIT collaboration). Acquire both and potential is limitless
4/30/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
3/2 Video Watchlist SCEI MELA RSYS MMR GA ATML ARIA SAH UCTT ALNY ACHN BTU REXX INAP ANW CNX ALSK http://www.bit.ly/A4YhPa
3/2/12
Reply (7)

• !Report Abuse
View all 7 replies
Ryan Mallory: sure will
3/6/12
• !Report Abuse
phemale60: has some useful information but I guess they are also trying to push their Biotech Supertrader program. Love their "quote of the day"!
3/6/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Alnylam Pharmaceuticals (ALNY) has a nice chart. Looks a little like another rounded bottom. http://bit.ly/wZi3Vx
2/15/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Tony Kau
$RRR and $ALNY looking to peak, $TECH and $R forming a bottom... more on http://bit.ly/vVGjCq
2/6/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

David White
ALNY up approx. 50% since my article in early Dec. 2011. Love it when a call works well.
1/18/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jim Van Meerten
ALNY - 96% Barchart technical buy signal - 15 new highs and up 27.02% in the last month - Relative Strength Index 68.01%
1/4/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Ryan Mallory
3/2 Video Watchlist SCEI MELA RSYS MMR GA ATML ARIA SAH UCTT ALNY ACHN BTU REXX INAP ANW CNX ALSK http://www.bit.ly/A4YhPa
3/2/12
Reply (7)

• !Report Abuse
View all 7 replies
Ryan Mallory: sure will
3/6/12
• !Report Abuse
phemale60: has some useful information but I guess they are also trying to push their Biotech Supertrader program. Love their "quote of the day"!
3/6/12
• !Report Abuse
Add a reply...

140 characters

ALNY Alnylam Pharmaceuticals, Inc.

ALNY

Alnylam Pharmaceuticals, Inc.